| Literature DB >> 11330477 |
J R Boyles1, M C Bair, B G Campling, N Jain.
Abstract
The compounds (eta5-C5H5)2TiCl2 (I), currently undergoing phase II trials, (eta5-C5H5)(eta5-C5H4CO2Me)TiCl2 (II) and C5H4CO2Me)2TiCl2 (III) are assessed for their efficacies against a small lung cancer cell line. It is found that the introduction of the electron withdrawing carbomethoxy group into the cyclopentadienyl rings increases the effectiveness of this class of drugs, such that III compares favorably with the well known cisplatin.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11330477 DOI： 10.1016/s0162-0134(00)00203-8
Source DB: PubMed Journal: J Inorg Biochem ISSN： 0162-0134 Impact factor: 4.155